vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $9.4M, roughly 1.6× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs 1.8%, a 1932.2% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs 10.1%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
BYFC vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $15.0M |
| Net Profit | $1.0M | $268.0K |
| Gross Margin | — | 51.7% |
| Operating Margin | — | 1.2% |
| Net Margin | 1934.0% | 1.8% |
| Revenue YoY | 10.1% | 11.5% |
| Net Profit YoY | -21.8% | -63.2% |
| EPS (diluted) | $0.02 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $15.0M | ||
| Q3 25 | $9.0M | $14.0M | ||
| Q2 25 | $8.1M | $12.4M | ||
| Q1 25 | $8.3M | $17.0M | ||
| Q4 24 | $8.6M | $13.5M | ||
| Q3 24 | $8.7M | $14.1M | ||
| Q2 24 | $8.2M | $14.0M | ||
| Q1 24 | $7.8M | $12.0M |
| Q4 25 | $1.0M | $268.0K | ||
| Q3 25 | $-23.9M | $-436.0K | ||
| Q2 25 | $752.0K | $-1.8M | ||
| Q1 25 | $-2.7M | $4.5M | ||
| Q4 24 | $1.3M | $728.0K | ||
| Q3 24 | $516.0K | $1.3M | ||
| Q2 24 | $256.0K | $-109.0K | ||
| Q1 24 | $-154.0K | $-2.5M |
| Q4 25 | — | 51.7% | ||
| Q3 25 | — | 42.9% | ||
| Q2 25 | — | 41.1% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 44.9% | ||
| Q3 24 | — | 49.7% | ||
| Q2 24 | — | 48.2% | ||
| Q1 24 | — | 34.7% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | -256.2% | -3.8% | ||
| Q2 25 | 12.8% | -16.2% | ||
| Q1 25 | -45.3% | 26.4% | ||
| Q4 24 | 21.7% | 5.4% | ||
| Q3 24 | 8.5% | 9.5% | ||
| Q2 24 | 4.8% | -1.9% | ||
| Q1 24 | -2.9% | -21.4% |
| Q4 25 | 1934.0% | 1.8% | ||
| Q3 25 | -264.2% | -3.1% | ||
| Q2 25 | 9.3% | -14.9% | ||
| Q1 25 | -32.3% | 26.4% | ||
| Q4 24 | 15.3% | 5.4% | ||
| Q3 24 | 5.9% | 9.3% | ||
| Q2 24 | 3.1% | -0.8% | ||
| Q1 24 | -2.0% | -21.1% |
| Q4 25 | $0.02 | $0.02 | ||
| Q3 25 | $-2.86 | $-0.03 | ||
| Q2 25 | $0.00 | $-0.12 | ||
| Q1 25 | $-0.39 | $0.31 | ||
| Q4 24 | $0.07 | $0.05 | ||
| Q3 24 | $-0.03 | $0.09 | ||
| Q2 24 | $0.02 | $-0.01 | ||
| Q1 24 | $-0.02 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $4.2M |
| Total Assets | $1.3B | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $8.5M | ||
| Q3 25 | $19.7M | $10.3M | ||
| Q2 25 | $29.5M | $9.8M | ||
| Q1 25 | $15.8M | $3.2M | ||
| Q4 24 | $61.4M | $2.8M | ||
| Q3 24 | $97.1M | $2.9M | ||
| Q2 24 | $89.8M | $2.6M | ||
| Q1 24 | $67.1M | $4.5M |
| Q4 25 | $262.8M | $4.2M | ||
| Q3 25 | $261.7M | $3.5M | ||
| Q2 25 | $284.7M | $3.8M | ||
| Q1 25 | $283.6M | $5.5M | ||
| Q4 24 | $285.0M | $681.0K | ||
| Q3 24 | $286.2M | $-332.0K | ||
| Q2 24 | $282.1M | $-1.9M | ||
| Q1 24 | $281.1M | $-2.1M |
| Q4 25 | $1.3B | $30.2M | ||
| Q3 25 | $1.3B | $30.5M | ||
| Q2 25 | $1.2B | $32.3M | ||
| Q1 25 | $1.3B | $30.6M | ||
| Q4 24 | $1.3B | $25.2M | ||
| Q3 24 | $1.4B | $24.9M | ||
| Q2 24 | $1.4B | $26.1M | ||
| Q1 24 | $1.4B | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-1.7M |
| Free Cash FlowOCF − Capex | $-13.0K | $-2.0M |
| FCF MarginFCF / Revenue | -0.1% | -13.1% |
| Capex IntensityCapex / Revenue | 2.6% | 1.6% |
| Cash ConversionOCF / Net Profit | 0.22× | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-1.7M | ||
| Q3 25 | $3.8M | $600.0K | ||
| Q2 25 | $3.0M | $6.9M | ||
| Q1 25 | $-4.3M | $490.0K | ||
| Q4 24 | $1.4M | $-283.0K | ||
| Q3 24 | $6.1M | $311.0K | ||
| Q2 24 | $9.8M | $-1.8M | ||
| Q1 24 | $-11.7M | $-919.0K |
| Q4 25 | $-13.0K | $-2.0M | ||
| Q3 25 | $3.7M | $554.0K | ||
| Q2 25 | $3.0M | $6.6M | ||
| Q1 25 | $-4.4M | $448.0K | ||
| Q4 24 | $1.3M | $-377.0K | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | $-1.8M | ||
| Q1 24 | $-11.7M | $-1.0M |
| Q4 25 | -0.1% | -13.1% | ||
| Q3 25 | 41.1% | 4.0% | ||
| Q2 25 | 37.0% | 53.5% | ||
| Q1 25 | -52.4% | 2.6% | ||
| Q4 24 | 14.7% | -2.8% | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | -13.0% | ||
| Q1 24 | -149.7% | -8.4% |
| Q4 25 | 2.6% | 1.6% | ||
| Q3 25 | 1.2% | 0.3% | ||
| Q2 25 | 0.2% | 2.0% | ||
| Q1 25 | 0.2% | 0.2% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.5% | 0.0% | ||
| Q1 24 | 0.7% | 0.8% |
| Q4 25 | 0.22× | -6.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | 1.06× | -0.39× | ||
| Q3 24 | 11.85× | 0.24× | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
